Although targeted therapies for estrogen receptor–positive (ER+) and ERBB2-amplified (human epidermal growth factor receptor 2–positive [HER2+]) breast cancers have become the mainstay of treatment over several decades, a rapidly growing number of novel agents are now emerging whose effectiveness may depend on specific genomic aberrations. This evidence concerns the gene ERBB2 and breast cancer.